
    
      All patients will be randomized in a 1:1 ratio to receive:

      ARM A:

      Bortezomib (V):

        -  1.3 mg/m2 subcutaneously on days 1, 4, 8, 11, 22, 25, 29 and 32 in cycles 1-4;

        -  1.3 mg/m2 subcutaneously on days 1, 8, 22 and 29 in cycles 5-9.

      Melphalan (M):

      - 9 mg/m2 orally on days 1, 2, 3 and 4 of each cycle.

      Prednisone (P):

      - 60 mg/m2 orally on days 1, 2, 3 and 4 of each cycle. Each cycle is to be repeated every 42
      days. Duration: Maximum 9 therapy cycles can be performed. After 9 cycles, patients will be
      observed until progression disease or the start of a new line of therapy.

      ARM B:

      Lenalidomide (R):

      - 25 mg orally on days 1-21 of each cycle.

      Dexamethasone (d):

      - 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.
      Duration: patients will receive treatment until any sign of progression or intolerance.
    
  